R190
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 105
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.500
- MYC_TARGETS_V1+0.460
- MTORC1_SIGNALING+0.450
- OXIDATIVE_PHOSPHORYLATION+0.420
- PROTEIN_SECRETION+0.410
- ANDROGEN_RESPONSE+0.400
- INTERFERON_GAMMA_RESPONSE+0.390
- MYC_TARGETS_V2+0.380
- E2F_TARGETS+0.360
- G2M_CHECKPOINT+0.330
Top 10 suppressed
- MYOGENESIS-0.360
- PANCREAS_BETA_CELLS-0.330
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.310
- HEDGEHOG_SIGNALING-0.250
- COAGULATION-0.230
- KRAS_SIGNALING_DN-0.230
- APICAL_JUNCTION-0.180
- UV_RESPONSE_UP-0.170
- ANGIOGENESIS-0.160
- SPERMATOGENESIS-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-DK-AA77-01A-11R-A39I-07 | — | — | 0.873 |
| 2 | MNG533 | — | — | 0.868 |
| 3 | TCGA-XF-AAN2-01A-11R-A42T-07 | — | — | 0.867 |
| 4 | BS_W80TJC27 | EPN | Supratentorial EPN | 0.861 |
| 5 | d5610bbc-93c5-4ca5-b687-f955d1b84c92 | — | — | 0.850 |
| 6 | 57AA1143-0FA1-4197-8CBE-517F6B885753 | — | — | 0.848 |
| 7 | R427 | — | — | 0.847 |
| 8 | BS_W80TJC27 | Supratentorial Ependymoma | — | 0.843 |
| 9 | 46E565A7-5022-4648-9035-B60FC7CFD6E7 | — | — | 0.842 |
| 10 | MNG1200 | — | — | 0.839 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.460 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.450 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.420 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.410 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.400 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.390 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.380 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.360 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.330 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.310 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.310 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.280 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.260 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.250 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.240 | Inavolisib | — uncovered |
| PEROXISOME | 0.220 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.210 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.210 | Inavolisib | — uncovered |
| APOPTOSIS | 0.160 | Idelalisib | — uncovered |